- Home
- VRAX vs ONCO Comparison
VRAX vs ONCO Comparison
Compare VRAX & ONCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VRAX
- ONCO
- Stock Information
- Founded
- VRAX 2013
- ONCO 2018
- Country
- VRAX United Kingdom
- ONCO United States
- Employees
- VRAX N/A
- ONCO N/A
- Industry
- VRAX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- ONCO Biotechnology: Pharmaceutical Preparations
- Sector
- VRAX Health Care
- ONCO Health Care
- Exchange
- VRAX Nasdaq
- ONCO Nasdaq
- Market Cap
- VRAX 7.3M
- ONCO 3.6M
- IPO Year
- VRAX 2022
- ONCO 2022
- Fundamental
- Price
- VRAX $1.44
- ONCO $0.14
- Analyst Decision
- VRAX
- ONCO
- Analyst Count
- VRAX 0
- ONCO 0
- Target Price
- VRAX N/A
- ONCO N/A
- AVG Volume (30 Days)
- VRAX 231.6K
- ONCO 868.6K
- Earning Date
- VRAX 02-05-2025
- ONCO 04-10-2025
- Dividend Yield
- VRAX N/A
- ONCO N/A
- EPS Growth
- VRAX N/A
- ONCO N/A
- EPS
- VRAX N/A
- ONCO N/A
- Revenue
- VRAX $84,872.00
- ONCO $1,870,605.00
- Revenue This Year
- VRAX $5,169.18
- ONCO N/A
- Revenue Next Year
- VRAX $66.97
- ONCO N/A
- P/E Ratio
- VRAX N/A
- ONCO N/A
- Revenue Growth
- VRAX 7.03
- ONCO N/A
- 52 Week Low
- VRAX $0.60
- ONCO $0.16
- 52 Week High
- VRAX $9.00
- ONCO $21.40
- Technical
- Relative Strength Index (RSI)
- VRAX 40.82
- ONCO 21.16
- Support Level
- VRAX $1.22
- ONCO $0.21
- Resistance Level
- VRAX $1.84
- ONCO $0.25
- Average True Range (ATR)
- VRAX 0.16
- ONCO 0.03
- MACD
- VRAX -0.01
- ONCO -0.01
- Stochastic Oscillator
- VRAX 35.62
- ONCO 7.64
About VRAX Virax Biolabs Group Limited
Virax Biolabs Group Ltd is a biotechnology company focused on the prevention, detection, diagnosis and risk management of viral diseases that also engages in distribution of diagnostics test kits of various viral threats. It is developing a proprietary T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against world-wide viral threats. T-Cell testing is particularly effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Hepatitis B, Malaria, Herpes and Human Papillomavirus.
About ONCO Onconetix Inc.
Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of innovative solutions for men's health and oncology. It has a product named Entadfi an FDA-approved once-daily oral therapeutic for the treatment of benign prostatic hyperplasia, a disorder of the prostate, along with building additional assets in therapeutics, diagnostics, and clinician services for oncology.